Strategic Partnerships Pharmaron’s expanding collaboration footprint with industry leaders such as Eli Lilly and CN Bio signals opportunities to position cross-referral programs, co-development services, and joint capability showcases to prospective pharma clients seeking integrated CRO/CDMO solutions.

CGT Expansion Recent investments in cell and gene therapy capabilities, including Liverpool CGT assets and viral vector/mRNA manufacturing capacity, create a compelling pitch for biotech clients pursuing scalable GMP CGT and early-phase manufacturing partnerships.

Global Platform A broad global development and manufacturing platform across small molecules, biologics, and CGT, coupled with a UK and Europe emphasis, offers a selling point for customers seeking end‑to‑end global development, multi-modality support, and regional manufacturing access.

Innovation Focus Strategic collaborations in organ-on-a-chip and advanced radiochemistry/radiosynthesis capabilities, along with investments in mRNA and gene therapy facilities, position Pharmaron as a source for cutting-edge methodologies that reduce development timelines for ambitious programs.

Scale and Reliability With a revenue range in the billions and a sizable workforce, Pharmaron demonstrates operating scale and capacity to de-risk large projects, offer flexible capacity planning, and support high-throughput screening, toxicology, and clinical development at pace for mid-to-large bio/pharma clients.